AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

Biomarkers can shape a breast cancer treatment plan, Andy Guinigundo explained in an interview with CURE.

Filmmaker Tahira Kashyap revealed on Instagram that her breast cancer had relapsed for the second time. In 2018, she had been ...

The EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing ...

The EC based its decision on data from the DESTINY-Breast06 trial, which included patients whose tumors had very low levels of HER2 expression.

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

Enhertu gains EU approval for treating advanced breast cancer with low HER2 levels, marking a milestone for Daiichi Sankyo & ...

Kaplan–Meier curves showed that extended adjuvant pyrotinib administered after trastuzumab-based adjuvant therapy provides a promising survival benefit in patients with high-risk HER2-positive breast ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Learn more about whether Intra-Cellular Therapies, Inc. or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ ...

Cell therapy and oncology–focused Carisma Therapeutics started layoffs late last year. Now the company plans to wind down ...